Gastrointestinal Cancer

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Tovecimig plus paclitaxel improved overall response rate vs paclitaxel alone in second-line advanced biliary tract cancer.

Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

Jennifer Chan, MD, MPH, discusses the FDA approval of cabozantinib for previously treated, advanced well-differentiated (extra) pancreatic neuroendocrine tumors.

The FDA has approved cabozantinib (Cabometyx) for use in select patients with pancreatic and extra-pancreatic neuroendocrine tumors.

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

For Anal Cancer Awareness Day, Sheela Rao, MBBS, MD, FRCP, discusses present and upcoming treatment strategies, unmet needs, and the future of the field.

Sheela Rao, MBBS, MD, FRCP, highlights the current treatment landscape in the localized anal cancer setting for anal cancer Awareness Day, March 21.

PEP-010 has been granted an orphan drug designation by the FDA for the treatment of patients with metastatic pancreatic cancer.

The FDA approved pembrolizumab, trastuzumab, and chemotherapy for HER2-positive, PD-L1–positive gastric/GEJ adenocarcinoma.

The FDA has granted orphan drug designation to HLX22 for the treatment of patients with gastric cancer based on positive data from the HLX22-GC-201 study.

Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.

Ajay Goel, PhD, AGAF, discusses the potential utility of CA19-9 with an exosome-based liquid biopsy as a diagnostic biomarker in early-stage pancreatic cancer.

The top 5 OncLive videos of the week cover insights in colorectal cancer, myeloma, HER2+ breast cancer, and KRAS G12X+ pancreatic ductal adenocarcinoma.

Vepdegestrant boosts PFS in select ESR1-mutated breast cancer, maintenance OSE2101 combination provides survival benefit in PDAC, and more from OncLive.

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Maintenance treatment with OSE2101 plus FOLFIRI after FOLFIRINOX induction chemotherapy displayed positive topline results in advanced/metastatic PDAC.

SAR444200-mediated targeting of GPC3-expressing solid tumors was safe and showed early signs of antitumor activity in a phase 1/2 study.

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.

Perioperative durvalumab plus FLOT improved event-free survival in resectable gastric or gastroesophageal junction cancer.